Leerink Partners Downgrades PRCT to Hold

Leerink Partners has downgraded its rating on PRCT to a Hold, setting a price target of $29. This change was announced on June 11, 2026, as analyst Mike Kratky adjusted his outlook on the stock. PRCT shares were trading at approximately $25.71 at the time of the downgrade.

Other Institutional Activity in PRCT

Several other institutional investors have also made moves in PRCT recently. BlackRock, Inc. increased its holdings by 14,969 shares, bringing its total to about 4.36 million shares valued at $109.1 million. T. Rowe Price Investment Management, Inc. added 2,386 shares, holding a total of approximately 3.27 million shares worth $81.9 million. Meanwhile, BNP Paribas Asset Management Holding S.A. reduced its position by 5,271 shares, leaving it with around 3.09 million shares valued at $77.3 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both initiated new positions with holdings of 2.42 million and 2.39 million shares, respectively.

PRCT Stock Snapshot

Shares of PRCT are currently trading near $25.71. The stock has been experiencing various levels of institutional interest, as evidenced by recent changes in holdings by major funds. The stock's performance and market interest are closely watched by investors and analysts alike.

Insider Buying and Selling at PROCEPT BioRobotics Corporation

Recent insider activity at PRCT includes several purchases on June 9, 2026. Desai Antal Rohit, Amy Dodrill, Thomas Prescott, Dan Puckett, and Mary Garrett each acquired shares, with the transactions involving 3,315 to 5,853 shares per insider. These transactions were not made under a Rule 10b5-1 plan, indicating discretionary buying.

Analysts Set New Price Targets

On June 11, 2026, Leerink Partners downgraded PRCT to a Hold with a $29 price target. Previously, on April 30, 2026, Piper Sandler reiterated its Buy rating with a $35 target. Baird initiated coverage on March 6, 2026, with a Hold rating and a $30 target. The analyst consensus reflects a mixed outlook, with a blend of Hold and Buy ratings.

Bottom Line

The recent downgrade by Leerink Partners highlights a cautious stance on PRCT, with a new Hold rating and a $29 target. Institutional investors have shown varying degrees of interest, with some funds increasing their stakes while others trim positions. Insider buying activity suggests confidence among those close to the company. As always, investors should consider these factors in the context of their own investment strategies.